The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival

Leukemia

Volumn 25, Issue 3, 2011, Pages 538-550

  Scuto, A ^a   Krejci, P ^b,c,d   Popplewell, L ^a   Wu, J ^a   Wang, Y ^a,a   Kujawski, M ^a   Kowolik, C ^a   Xin, H ^a   Chen, L ^a   Kretzner, L ^a   Yu, H ^a   Wilcox, W R ^d,e   Yen, Y ^a   Forman, S ^a   Jove, R ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b MASARYK UNIVERSITY   (Czech Republic)

^c INSTITUTE OF BIOPHYSICS   (Czech Republic)

^d CEDARS SINAI MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

FGFR3; JAK2; myeloma; STAT3

Indexed keywords

ANTINEOPLASTIC AGENT; AZD 1480; CYCLIN D2; DOXORUBICIN; FIBROBLAST GROWTH FACTOR RECEPTOR 3; INTERLEUKIN 6; JANUS KINASE 2; MELPHALAN; MITOGEN ACTIVATED PROTEIN KINASE; STAT3 PROTEIN; SYNDECAN 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN; CELL STRAIN IM 9; CELL STRAIN KMS 11; CELL STRAIN KMS 18; CELL STRAIN MM1 S; CELL STRAIN NCI H929; CELL STRAIN OPM 2; CELL STRAIN RPMI 8226; CELL STRAIN U266; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE TARGETING; HUMAN; HUMAN CELL; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR XENOGRAFT;

EID: 79952452004     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.289     Document Type: Article

References (58)

1. Kyle RA, Rajkumar SV. Multiple myeloma. Blood 2008; 111: 2962-2972. .
2. Fonseca R, Stewart AK. Targeted therapeutics for multiple myeloma: the arrival of a risk-stratified approach. Mol Cancer Ther 2007; 6: 802-810. . (Pubitemid 46554550)
3. San-Miguel J, Harousseau JL, Joshua D, Anderson KC. Individualizing treatment of patients with myeloma in the era of novel agents. J Clin Oncol 2008; 26: 2761-2766. .
4. Ocio EM, Mateos MV, Maiso P, Pandiella A, San-Miguel JF. New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. Lancet Oncol 2008; 9: 1157-1165. .
5. Vallet S, Palumbo A, Raje N, Boccadoro M, Anderson KC. Thalidomide and lenalidomide: mechanism-based potential drug combinations. Leuk Lymphoma 2008; 49: 1238-1245. . (Pubitemid 352015786)
6. Richardson PG, Mitsiades C, Schlossman R, Ghobrial I, Hideshima T, Munshi N et al. Bortezomib in the front-line treatment of multiple myeloma. Expert Rev Anticancer Ther 2008; 8: 1053-1072. .
7. Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 2008; 112: 1593-1599. .
8. Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008; 22: 414-423. . (Pubitemid 351255436)
9. Bommert K, Bargou RC, Stuhmer T. Signalling and survival pathways in multiple myeloma. Eur J Cancer 2006; 42: 1574-1580. . (Pubitemid 44118772)
10. Kawano MM, Ishikawa H, Tsuyama N, Abroun S, Liu S, Li FJ et al. Growth mechanism of human myeloma cells by interleukin-6. Int J Hematol 2002; 76 (Suppl 1): 329-333. .
11. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999; 10: 105-115. . (Pubitemid 29077388)
12. Ogata A, Chauhan D, Teoh G, Treon SP, Urashima M, Schlossman RL et al. IL-6 triggers cell growth via the Rasdependent mitogen-activated protein kinase cascade. J Immunol 1997; 159: 2212-2221. . (Pubitemid 127681011)
13. Bharti AC, Donato N, Aggarwal BB. Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol 2003; 171: 3863-3871. . (Pubitemid 37254592)
14. Amit-Vazina M, Shishodia S, Harris D, Van Q, Wang M, Weber D et al. Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells. Br J Cancer 2005; 93: 70-80. . (Pubitemid 41076255)
15. De Vos J, Jourdan M, Tarte K, Jasmin C, Klein B. JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogenactivated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells. Br J Haematol 2000; 109: 823-828. . (Pubitemid 30609763)
16. Pedranzini L, Dechow T, Berishaj M, Comenzo R, Zhou P, Azare J et al. Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells. Cancer Res 2006; 66: 9714-9721. . (Pubitemid 44623672)
17. Burger R, Le Gouill S, Tai YT, Shringarpure R, Tassone P, Neri P et al. Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo. Mol Cancer Ther 2009; 8: 26-35. .
18. Hedvat M, Huszar D, Herrmann A, Gozgit JM, Schroeder A, Sheehy A et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 2009; 16: 487-497. .
19. Krejci P, Salazar L, Kashiwada TA, Chlebova K, Salasova A, Thompson LM et al. Analysis of STAT1 activation by six FGFR3 mutants associated with skeletal dysplasia undermines dominant role of STAT1 in FGFR3 signaling in cartilage. PloS one 2008; 3: e3961. .
20. Heale BS, Soifer HS, Bowers C, Rossi JJ. siRNA target site secondary structure predictions using local stable substructures. Nucleic Acids Res 2005; 33: e30. .
21. Scherer LJ, Yildiz Y, Kim J, Cagnon L, Heale B, Rossi JJ. Rapid assessment of anti-HIV siRNA efficacy using PCR-derived Pol III shRNA cassettes. Mol Ther 2004; 10: 597-603. . (Pubitemid 39186120)
22. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C et al. Stat3 as an oncogene. Cell 1999; 98: 295-303. . (Pubitemid 29380565)
23. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006; 58: 621-681. .
24. Ogata A, Chauhan D, Urashima M, Teoh G, Treon SP, Anderson KC. Blockade of mitogen-activated protein kinase cascade signaling in interleukin 6-independent multiple myeloma cells. Clin Cancer Res 1997; 3: 1017-1022. . (Pubitemid 27253011)
25. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003; 374 (Part 1): 1-20. . (Pubitemid 37046923)
26. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 1998; 334 (Part 2): 297-314. . (Pubitemid 28448572)
27. Zhang B, Fenton RG. Proliferation of IL-6-independent multiple myeloma does not require the activity of extracellular signalregulated kinases (ERK1/2). J Cell Physiol 2002; 193: 42-54. . (Pubitemid 34969127)
28. Puthier D, Bataille R, Amiot M. IL-6 up-regulates mcl-1 in human myeloma cells through JAK / STAT rather than ras/MAP kinase pathway. Eur J Immunol 1999; 29: 3945-3950. .
29. Meads MB, Hazlehurst LA, Dalton WS. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res 2008; 14: 2519-2526. .
30. Nefedova Y, Landowski TH, Dalton WS. Bone marrow stromalderived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia 2003; 17: 1175-1182. . (Pubitemid 36722250)
31. Chesi M, Brents LA, Ely SA, Bais C, Robbiani DF, Mesri EA et al. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood 2001; 97: 729-736. . (Pubitemid 32113407)
32. Chesi M, Nardini E, Brents LA, Schrock E, Ried T, Kuehl WM et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 1997; 16: 260-264. . (Pubitemid 27280209)
33. Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003; 101: 4569-4575. . (Pubitemid 36857829)
34. Grigorieva I, Thomas X, Epstein J. The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone. Exp Hematol 1998; 26: 597-603. . (Pubitemid 28307527)
35. Nefedova Y, Cheng P, Alsina M, Dalton WS, Gabrilovich DI. Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood 2004; 103: 3503-3510. . (Pubitemid 38525684)
36. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy Jr J. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 2005; 106: 296-303. . (Pubitemid 40967205)
37. Yang Y, Ochando J, Yopp A, Bromberg JS, Ding Y. IL-6 plays a unique role in initiating c-Maf expression during early stage of CD4 T cell activation. J Immunol 2005; 174: 2720-2729. . (Pubitemid 40279687)
38. Schaper F, Gendo C, Eck M, Schmitz J, Grimm C, Anhuf D et al. Activation of the protein tyrosine phosphatase SHP2 via the interleukin-6 signal transducing receptor protein gp130 requires tyrosine kinase Jak1 and limits acute-phase protein expression. Biochem J 1998; 335 (Part 3): 557-565. . (Pubitemid 28515408)
39. Guschin D, Rogers N, Briscoe J, Witthuhn B, Watling D, Horn F et al. A major role for the protein tyrosine kinase JAK1 in the JAK/ STAT signal transduction pathway in response to interleukin-6. Embo J 1995; 14: 1421-1429. .
40. Hurt EM, Wiestner A, Rosenwald A, Shaffer AL, Campo E, Grogan T et al. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell 2004; 5: 191-199. . (Pubitemid 38283804)
41. Shou Y, Martelli ML, Gabrea A, Qi Y, Brents LA, Roschke A et al. Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc Natl Acad Sci USA 2000; 97: 228-233. . (Pubitemid 30055813)
42. Wen XY, Stewart AK, Sooknanan RR, Henderson G, Hawley TS, Reimold AM et al. Identification of c-myc promoter-binding protein and X-box binding protein 1 as interleukin-6 target genes in human multiple myeloma cells. Int J Oncol 1999; 15: 173-178. .
43. Wuilleme-Toumi S, Robillard N, Gomez P, Moreau P, Le Gouill S, Avet-Loiseau H et al. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia 2005; 19: 1248-1252. . (Pubitemid 40946011)
44. Zhang B, Gojo I, Fenton RG. Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood 2002; 99: 1885-1893. . (Pubitemid 34525465)
45. Oshiro MM, Landowski TH, Catlett-Falcone R, Hazlehurst LA, Huang M, Jove R et al. Inhibition of JAK kinase activity enhances Fas-mediated apoptosis but reduces cytotoxic activity of topoisomerase II inhibitors in U266 myeloma cells. Clin Cancer Res 2001; 7: 4262-4271. . (Pubitemid 34044653)
46. Jourdan M, Veyrune JL, De Vos J, Redal N, Couderc G, Klein B. A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells. Oncogene 2003; 22: 2950-2959. . (Pubitemid 36648922)
47. Zhou Q, Yao Y, Ericson SG. The protein tyrosine phosphatase CD45 is required for interleukin 6 signaling in U266 myeloma cells. Int J Hematol 2004; 79: 63-73. . (Pubitemid 38182204)
48. Muto A, Hori M, Sasaki Y, Saitoh A, Yasuda I, Maekawa T et al. Emodin has a cytotoxic activity against human multiple myeloma as a Janus-activated kinase 2 inhibitor. Mol Cancer Ther 2007; 6: 987-994. . (Pubitemid 46554568)
49. Zhang B, Potyagaylo V, Fenton RG. IL-6-independent expression of Mcl-1 in human multiple myeloma. Oncogene 2003; 22: 1848-1859. . (Pubitemid 36513143)
50. Podar K, Chauhan D, Anderson KC. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 2009; 23: 10-24. .
51. Chatterjee M, Honemann D, Lentzsch S, Bommert K, Sers C, Herrmann P et al. In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/ gp130/STAT3 pathway. Blood 2002; 100: 3311-3318. . (Pubitemid 35217082)
52. Alas S, Bonavida B. Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clin Cancer Res 2003; 9: 316-326. . (Pubitemid 36109748)
53. Krejci P, Murakami S, Prochazkova J, Trantirek L, Chlebova K, Ouyang Z et al. NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells. J Biol Chem 2010; 285: 20644-20653. .
54. Nelson EA, Walker SR, Kepich A, Gashin LB, Hideshima T, Ikeda H et al. Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3. Blood 2008; 112: 5095-5102. .
55. Ronchetti D, Greco A, Compasso S, Colombo G, Dell'Era P, Otsuki T et al. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations. Oncogene 2001; 20: 3553-3562. . (Pubitemid 32619408)
56. Ramakrishnan V, Timm M, Haug JL, Kimlinger TK, Wellik LE, Witzig TE et al. Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs. Oncogene 2010; 29: 1190-1202. .
57. Li P, Harris D, Liu Z, Liu J, Keating M, Estrov Z. Stat3 activates the receptor tyrosine kinase like orphan receptor-1 gene in chronic lymphocytic leukemia cells. PloS One 2010; 5: e11859. .
58. Chebel A, Kagialis-Girard S, Catallo R, Chien WW, Mialou V, Domenech C et al. Indirubin derivatives inhibit malignant lymphoid cell proliferation. Leuk Lymphoma 2009; 50: 2049-2060.